Abstract 85P
Background
Tumor-associated macrophages (TAMs) are known to support tumor growth and progression in multiple cancers, including prostatic adenocarcinoma (PCa). However, the mechanisms behind macrophage re-education by cancer cells are still mostly unknown. Main aim of this project is to dissect the mechanisms utilised by the tumour to train macrophages in its favour. Our final purpose is to find molecular targets that may be exploited to develop novel immunotherapies or more efficient combinatorial approaches for the treatment of cancer.
Methods
We employed a genome wide CRISPRi screening to tumour-conditioned macrophages, with the aim of identifying targets capable of reverting macrophage activation toward an anti-tumour state. We then validated the results of the library using multiparametric Flow Cytometry analysis and immunofluorescence assays and we employed mouse models of prostate cancer to test in vivo promising targets identified by the screening.
Results
We identified a group of genes that codify for chemosensor receptors and act as regulators of pro-tumoral functions in TAMs. Genetic deletion of selected chemosensors re-educates CD206bright MHC-IIneg pro-tumoral macrophages and confer to these cells a CD206negMHC-IIbright pro-inflammatory phenotype. Functionally, chemosensors depleted macrophages (chemKO Macs) supported CD8+ cell proliferation and inhibited migration of tumour cells in vitro. In vivo, administration of chemKO Macs to tumour bearing mice resulted in a reduced tumour growth. Moreover, tumours from mice injected with chemKO Macs showed an altered tumour microenvironment enriched in tumour specific CD8+ CD39+ T cells. Additionally, we detected the expression of the chemosensor receptor OR51E2 on primary human macrophages in vitro and in tumor-infiltrating macrophages in tissues from PCa patients, therefore recapitulating our findings in a human setting. Finally, we identified palmitic acid as a ligand of OR51E2 and we confirmed its expression in human biopsies from PCa patients.
Conclusions
Our results identified novel targets that could be manipulated to re-educate the macrophage compartment in PCa.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Associazione Italiana per la Ricerca sul cancro (AIRC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract